MEMBER LOGIN


Follow MVCC on:

Follow MVCC on Facebook
Disease Site:

Clinical Trials

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Disease Site: Lung
Protocol Number: A081105
Status: OPEN
Key Eligibility: Prev registration to A151216; EGF exon 19 deletion or L858R mutation; completely resected stage IB, II, or IIIA non-squamous w/neg margins
Description:
Randomized Phase II Double Blind Study of Adjuvant Regorafenib vs Placebo in Patients with Node Positive Esophageal Cancer that Completed Pre-operative Therapy
Disease Site: Gastrointestinal
Protocol Number: RU021212I
Status: OPEN
Key Eligibility: Node positive (any T stage N1-3) proximal esophageal, distal esophagus or gastroesophageal (GE) junction adenocarcinoma after completing preoperative chemoradiation and surgery; No metastatic or recurrent disease; no R1 or R2 resection
Description:
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Disease Site: Lung
Protocol Number: E4512
Status: OPEN
Key Eligibility: Complete resection of stage IB, II, or IIIA NSCLC; registration to ALCHEMIST-SCREEN (A151216); Positive for translocation or inversion events involving the ALK gene locus
Description:
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib vs Placebo as Adjuvant Treatment in Patients with Germline BRCA ½ Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Disease Site: Breast
Protocol Number: B55
Status: OPEN
Key Eligibility: Non-metastatic triple negative; must have rcvd adjuvant therapy; documented BRCA 1 or 2 deleterious mutation; no prior PARP inhibitor
Description:
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
Disease Site: Gynecologic
Protocol Number: GOG 3004
Status: OPEN
Key Eligibility: High risk, stage III-IV BRCA mutated high grade serous or endometriod ovarian cancer, primary peritoneal cancer and/or fallopian tube cancer; must complete 1st line platinum based therapy
Description:
STUDY: ALLIANCE A031201 PHASE III TRIAL OF ENZALUTAMIDE (NSC # 766085) VERSUS ENZALUTAMIDE, ABIRATERONE AND PREDNISONE FOR CASTRATION RESISTANT METASTATIC PROSTATE CANCER
Disease Site: Genitourinary
Protocol Number: A031201
Status: OPEN
Key Eligibility: Progressive CRPC; no prior taxane-based chemo for met disease; no prior antiandrogen or androgen synthesis inhibitor
Description:
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Disease Site: Breast
Protocol Number: RU011201I
Status: OPEN
Key Eligibility: Stage IIIC or IV not amenable to local therapy; HER2-; no more than 1 prior therapy for advanced disease
Description:
**THE FOLLOWING PHYSICIANS HAVE BEEN APPROVED TO ENROLL: SOORI, BLOCK, Berg, Peterson, Avery – all non-approved physicians must enroll any eligible subjects through these physicians at the following sites: NCS (BERGAN, LEGACY), NHO, SENCC
A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Disease Site: Hematology
Protocol Number: E1912
Status: OPEN
Key Eligibility: CLL; no prior tx for CLL/SLL; >19 and <70; no corticosteroids for CLL
Description:
A PHASE III STUDY OF POSTOPERATIVE RADIATION THERAPY (IMRT) +/- CETUXIMAB FOR LOCALLY-ADVANCED RESECTED HEAD AND NECK CANCER
Disease Site: Head/Neck
Protocol Number: R0920
Status: OPEN
Key Eligibility: Resected squamous head/neck; T1, N1-2 OR T2-4a, N0-2, M0; No primary hypopharynx; No prior invasive malignancy
File: Download
Description:
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Disease Site: Breast
Protocol Number: NSABP B-51
Status: open
Key Eligibility: T1-3, N1 breast cancer at diagnosis (before neoadjuvant therapy); No metastatic disease
Description:
A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver
Disease Site: Neuroendocrine
Protocol Number: E2212
Status: OPEN
Key Eligibility: Histologically or pathologically confirmed metastatic low or intermediate grade pancreatic neuroendocrine tumor(s) to liver
Description:
APHASE III, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF SORAFENIB IN DESMOID TUMORS OR AGGRESSIVE FIBROMATOSIS (DT/DF)
Disease Site: Carcinoid
Protocol Number: A091105
Status: OPEN
Key Eligibility: DT/DF; prev locoregional therapy; no sorafenib; no con tx w/CYP3A4 inhibitors or inducers
Description:
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Disease Site: Lung
Protocol Number: E2511
Status: OPEN
Key Eligibility: Extensive stage SCLC; no prior SCLC therapy
Description:
Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients with Previously Untreated Low Tumor Burden Indolent Non-Hodgkin’s Lymphoma
Disease Site: Hematology
Protocol Number: PrE0401
Status: OPEN
Key Eligibility: Grade 1 or 2 follicular NHL (Stage III or IV); no large cell; low tumor burden
Description:
Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Disease Site: Hematology
Protocol Number: E1A11
Status: OPEN
Key Eligibility: Symptomatic standard-risk multiple myeloma
Description:
Randomized Phase II Study of AB (nab-paclitaxel [Abraxane™], Bevacizumab) versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative)
Disease Site: Melanoma
Protocol Number: RU261206I
Status: OPEN
Key Eligibility: Surgically unresectable stage IV malignant melanoma; no prior met melanoma therapy; no brain mets
Description:
The following physicians have asked to participate and have completed their paperwork/training and are able to enroll to this trial:  Hauke, Soori, Hutchins, Avery, Berg, Peterson, Renno, Block, Shah, and Green
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.
Disease Site: Breast
Protocol Number: S1207
Status: OPEN
Key Eligibility: ER/PR, HER-2 negative invasive breast carcinoma; no metastatic disease; high risk
Description:
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Disease Site: Hematology
Protocol Number: S1211
Status: OPEN
Key Eligibility: Newly diagnosed, high risk, active MM; one prior cycle of chemo ok
Description:
Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy
Disease Site: Gastrointestinal
Protocol Number: S1115
Status: OPEN
Key Eligibility: Metastatic pancreatic adenocarcinoma; no endocrine/neuroendocrine, lymphoma, or ampullary; Second line
Description:
A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC
Disease Site: Lung
Protocol Number: E1512
Status: OPEN
Key Eligibility: Stage IV, predominant non-squamous; no SCLC
Description:
A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
Disease Site: Cancer Control
Protocol Number: S1202
Status: OPEN
Key Eligibility: ER and/or PgR+, Stage I-III Brca; mastectomy or breast sparing surgery, post-menopausal
Description:
A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients
Disease Site: Breast
Protocol Number: SCUSF 1102
Status: OPEN
Key Eligibility: Newly dx brca prior to surgery; includes in situ and invasive - stages 0-III; no previous cancer except non-melanoma skin cancer
Description:
A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
Disease Site: Melanoma
Protocol Number: E3612
Status: OPEN
Key Eligibility: Untreated or prev recvd 1 tx for measurable, unresectable Stage III or IV melanoma
Description:
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
Disease Site: Hematology
Protocol Number: E1412
Status: OPEN
Key Eligibility: Confirmed DLBCL expressing CD20 antigen; NO primary mediastinal large B-cell lymphoma; NO stage II-IV non-bulky disease
Description:
NSABP Patient Registry and Biospecimen Profiling Repository
Disease Site: Gastrointestinal
Protocol Number: MPR-1
Status: OPEN
Key Eligibility: Metastatic colorectal cancer; available block from primary tumor
Description:
A RANDOMIZED PHASE II STUDY OF INDIVIDUALIZED COMBINED MODALITY THERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
Disease Site: Lung
Protocol Number: R1306
Status: PRE-ACTIVATION
Key Eligibility: Newly diagnosed NSCLC; unresectable Stage IIIA or B disease
Description:
RT CREDENTIALING REQUIRED PRIOR TO PARTICIPATION
A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence
Disease Site: Head/Neck
Protocol Number: E1311
Status: OPEN
Key Eligibility: Persistent lymph node disease following primary concurrent chemoradiotherapy of locoregionally advanced stage III/IV HNSCC of oral cavity, oropharynx, larynx, or hypopharynx
Description:
A RANDOMIZED, PLACEBO CONTROLLED PHASE II TRIAL OF AFATINIB (BIBW2992) AS ADJUVANT THERAPY FOLLOWING CHEMORADIATION IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA AT HIGH RISK OF RECURRENCE
Disease Site: Head/Neck
Protocol Number: R1008
Status: OPEN
Key Eligibility: Malignant major or minor salivary gland tumor
Description:
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Disease Site: Gastrointestinal
Protocol Number: S0820
Status: OPEN
Key Eligibility: Stage 0-III; tx w/SOC w/resection alone or in combination w/adjuvant therapy
Description:
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, Alliance IND# 15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Disease Site: Brain
Protocol Number: A071101
Status: OPEN
Key Eligibility: Hist dx of GMB at first-occurrence; 1st or 2nd recurrence considered resectable
Description:
Phase I/Randomized Phase II Trial of either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)
Disease Site: Brain
Protocol Number: N0877
Status: OPEN
Key Eligibility: Newly diagnosed GBM
Description:
PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB (NSC # 737754, IND 75648) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS
Disease Site: Carcinoid
Protocol Number: A021202
Status: OPEN
Key Eligibility: low or intermediate grade neuroendocrine carcinoma; unresectable or met carcinoid in foregut, midgut, hindgut or other non-pancreatic site
Description:
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme
Disease Site: Brain
Protocol Number: A221101
Status: OPEN
Key Eligibility: Stable glioblastoma; has undergone surgery or biopsy and already tx w/concurrent RT and chemo
Description:
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Disease Site: Breast
Protocol Number: E1Z11
Status: OPEN
Key Eligibility: Post-menopausal women; ER/PR + stage I-III adenocarcinoma of breast
Description:
Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Disease Site: Head/Neck
Protocol Number: E3311
Status: OPEN
Key Eligibility: Newly dx squamous cell or undifferentiated carcinoma of oropharynx; resectable disease; stage III, IV, or IVb
Description:
RANDOMIZED PHASE II STUDY COMPARING CABOZANTINIB (NSC #761968 AND IND #116059) WITH COMMERCIALLY SUPPLIED SUNITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
Disease Site: Genitourinary
Protocol Number: A031203
Status: OPEN
Key Eligibility: locally advanced or metastatic renal w/clear cell component
Description:
Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) plus Everolimus in Post-Menopausal Patients with Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy
Disease Site: Breast
Protocol Number: PrE0102
Status: OPEN
Key Eligibility: Adenocarcinoma of breast; stage IV or inoperable locally advanced disease
Description:
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer
Disease Site: Breast
Protocol Number: N093B
Status: OPEN
Key Eligibility: Metastatic, unresected, triple negative breast ca; post-menopausal
Description:
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)
Disease Site: Genitourinary
Protocol Number: PrE0801
Status: OPEN
Key Eligibility: Recurrent or metastatic renal following adjuvant tx
Description:
A Phase III Clinical Trial Comparing the Combination of Docetaxel plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Disease Site: Breast
Protocol Number: B49
Status: OPEN
Key Eligibility: HER2 Negative; adjuvant
Description:
A PHASE III TRIAL OF SHORT TERM ANDROGEN DEPRIVATION WITH PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPPORT) IN PROSTATE CANCER PATIENTS WITH A RISING PSA AFTER RADICAL PROSTATECTOMY
Disease Site: Genitourinary
Protocol Number: R0534
Status: OPEN
Key Eligibility: adenocarcinoma tx'ed primarily w/radical prostatectomy; lympy negative; no prior androgen dep ttx started after prostatectomy orprior to registration
Description:
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with
Disease Site: Brain
Protocol Number: N0872
Status: OPEN
Key Eligibility: Glioblastoma multiforme (grade 4 astrocytoma)
File: Download
Description:
Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo-
Disease Site: Cancer Control
Protocol Number: N10C1
Status: OPEN
Key Eligibility: Post-Menopausal w/history of breast or gynecologic CA - no current disease; significant vaginal complaints
File: Download
Description:
Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer
Disease Site: Gastrointestinal
Protocol Number: N0949
Status: OPEN
Key Eligibility: >70 yrs
Description:
A PHASE III RANDOMIZED TRIAL OF METFORMIN VERSUS PLACEBO ON RECURRENCE AND SURVIVAL IN EARLY STAGE BREAST CANCER
Disease Site: Breast
Protocol Number: MA32
Status: OPEN
Key Eligibility: Invasive breast cancer dx'ed and resected wtihin 12 months prior to randomization. No prior breast cancer.
Description:
A Phase III Study Evaluating the Role of Perioperative Chemotherapy in Patients with Potentially Resectable Hepatic Colorectal Metastases
Disease Site: Gastrointestinal
Protocol Number: NSABP C11
Status: OPEN
Key Eligibility: Histologic confirmation of colorectal adenocarcinoma, no anal, small bowel, or appendiceal carcinoma or any other colorectal malignant diseases (sarcoma, lymphoma, carcinoid)
Description:
A Randomized Phase III Trial of Adjuvant Therapy Comparing
Disease Site: Breast
Protocol Number: B47
Status: OPEN
Key Eligibility: The tumor must be unilateral invasive adenocarcinoma of the breast on histologic exam; HER2 status of the primary tumor must be evaluated prior to randomization; all testing performed must indicate that the tumor is HER2-low
Description:
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Disease Site: Breast
Protocol Number: E2108
Status: OPEN
Key Eligibility: Patients (male or female) must have an intact primary (not recurrent) invasive
Description:
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Disease Site: Breast
Protocol Number: CTSU S1007
Status: OPEN
Key Eligibility: ADJUVANT BREAST - Step 1 - hist confirmed dx of node pos(1-3 nodes) invasive br ca w/pos estrogen and/or progesterone receptor status,and neg HER-2; Step 2 - Recurrence score (RS) by Oncotype DX® must be less than or equal to 25
Description:
A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB NonSquamous NSCLC after Definitive Chemoradiation
Disease Site: Lung
Protocol Number: E6508
Status: OPEN
Key Eligibility: NSCLC, Nonsquamous, IIIA and IIIB
Description:

No IMRT or 4D RT is allowed on this trial.  The treating RT facility must have an approved 3D RT Benchmark on file with QARC.

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Disease Site: Hematology
Protocol Number: E3A06
Status: OPEN
Key Eligibility: Assymptomatic, high-risk, smoldering multiple myeloma
Description:
A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab, in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Disease Site: Gastrointestinal
Protocol Number: E7208
Status: OPEN
Key Eligibility: Met or adv CRC, KRAS-wild type, first line tx with Oxaliplatin-containing chemo and Avastin. PD within 90 days of last Avastin.
Description:
A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen
Disease Site: Breast
Protocol Number: E3108
Status: OPEN
Key Eligibility: Stage III/Stage IV. No prior tx. No prior Tamoxifen
Description:
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Disease Site: Gastrointestinal
Protocol Number: C80702
Status: OPEN
Key Eligibility: Resected Stage III Colon
Description:
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Disease Site: Lung
Protocol Number: E5508
Status: OPEN
Key Eligibility: Advanced NSCLC, Non-Squamous
Description:
Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV NSCLC
Disease Site: Lung
Protocol Number: C30607
Status: OPEN
Key Eligibility: NSCLC, Stage IIIB or IV First Line
Description:
A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma
Disease Site: Melanoma
Protocol Number: N0879
Status: OPEN
Key Eligibility: Metastatic Melanoma
Description:
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Disease Site: Breast
Protocol Number: B43
Status: OPEN
Key Eligibility: DCIS HER2 testing by NSABP
Description:
A Prospective Observational Multi-Center Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment
Disease Site: Cancer Control
Protocol Number: S0702
Status: OPEN
Key Eligibility: Pts Starting Zoledronic Acid / Osteonecrosis of the Jaw
Description:

OMAHA:Use Omaha IC
LINC: Use Lincoln IC
 

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
Disease Site: Lung
Protocol Number: C30610
Status: OPEN - Omaha sites only
Key Eligibility: SMALL CELL, Limited Stage
Description:

OMAHA:Use Omaha IC
Not avail to Lincoln yet
 

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab With or Without Concurrent Avastin® for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)
Disease Site: Hematology
Protocol Number: RC0783
Status: OPEN
Key Eligibility: Untreated CLL
Description:
A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
Disease Site: Head/Neck
Protocol Number: E1305
Status: OPEN
Key Eligibility: Recurrent or Metastatic H&N
Description:
Randomized Phase III Trial Comparing the Frequency of Major Erythroid
Disease Site: Hematology
Protocol Number: E2905
Status: OPEN
Key Eligibility: Low- or Intermediate- MDS and Symptomatic Anemia
Description:
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
Disease Site: Genitourinary
Protocol Number: RTOG 0815
Status: OPEN. RT credentialing required
Key Eligibility: Prostate, Intermediate-Risk, RT
Description:

Note: RT site credentialing pending – please check prior to screening/enrollment.

A Double Blind Phase II Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
Disease Site: Genitourinary
Protocol Number: C90601
Status: OPEN
Key Eligibility: Advanced Bladder, Transitional Cell
Description:
Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
Disease Site: Genitourinary
Protocol Number: C90203
Status: OPEN
Key Eligibility: Prostate, NeoAdjuvant, High-Risk, Clinically Localized
Description:
A Randomized Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Disease Site: Breast
Protocol Number: C70604
Status: OPEN
Key Eligibility: Metastatic Breast, No Prior Zometa
Description:
Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma
Disease Site: Brain
Protocol Number: N0577
Status: OPEN
Key Eligibility: 1p/19q Co-deleted Anaplastic Glioma
Description:
Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Disease Site: Brain
Protocol Number: E3F05
Status: OPEN
Key Eligibility: Symptomatic Gliomas
Description:
Missouri Valley Cancer Consortium
6818 Grover Street * Executive Plaza, Suite 200 * Omaha, NE 68106
(402) 991-8070